China: Shanghai ZhenGe Biotech, a one-stop CDMO with expertise across monoclonal and bispecific antibodies, Antibody Drug Conjugates (ADC), fusion proteins and vaccines, has completed a round C financing of US$100m. The round was led by Goldman Sachs Asset Management (GSAM) and Sofina. Also investing were Novo Holdings, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital…
Home Healthcare Markets International News Funding rounds: Desentum, River BioMedics, Smarter Health, Healthcare At Home India, Shanghai...